ROCKVILLE, Md., Oct. 30,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. ET to discuss its financial results for
the third quarter ended September 30,
2024, and recent operational highlights.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company's investor website approximately two hours after the call's
conclusion. Those who plan on participating are advised to join 15
minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. Since its founding in 2009, REGENXBIO has
pioneered the development of AAV Therapeutics, an innovative class
of gene therapy medicines. REGENXBIO is advancing a
pipeline of AAV Therapeutics for rare and retinal diseases,
including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for
the treatment of wet AMD and diabetic retinopathy, being developed
in collaboration with AbbVie, and RGX-121 for the treatment of MPS
II. Thousands of patients have been treated
with REGENXBIO's AAV Therapeutic platform, including
Novartis' Zolgensma® for children with spinal
muscular atrophy. Designed to be one-time treatments, AAV
Therapeutics have the potential to change the way healthcare is
delivered for millions of people. For more information, please
visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate
Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor
Relations
IR@regenxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-6-to-discuss-third-quarter-2024-financial-results-and-recent-operational-highlights-302291244.html
SOURCE REGENXBIO Inc.